Core Viewpoint - The ongoing dispute between Changchun Shengboma and New Oxygen Youth Clinic highlights the complexities of compliance and pricing mechanisms in the domestic medical beauty filler market, specifically regarding the product "Aivilan" [1][2] Group 1: Industry Dynamics - The traditional medical beauty market has seen supply-side dominance over pricing, where the cost of consumables, manufacturer profits, and channel premiums dictate the final price [2][5] - The pricing formula can be simplified as: Price = Consumable Cost + Manufacturer Profit + Channel Premium [2] - Manufacturers retain over 90% gross profit margins, leaving minimal profit for other channels and institutions [5][10] Group 2: Pricing Mechanisms - The pricing structure involves multiple layers of markup from manufacturers to distributors and ultimately to medical institutions, leading to significant price inflation [5][6] - For example, the market price of Juvederm Ultra 4 in South Korea is around 2000 RMB, while in first-tier Chinese cities, it can exceed 6000 RMB due to various markups [5][10] - Manufacturers employ various strategies to maintain price control, including supply adjustments, legal pressure on price-cutting distributors, and limiting access to authenticity verification channels [6][10] Group 3: Consumer Perspectives - Consumers often oppose the manufacturers' pricing logic, advocating for transparency and market-driven pricing rather than excessive premiums [2][15] - The dichotomy between the medical attributes of beauty services and their consumer aspects reflects a fundamental conflict in the industry [2][14] - The current pricing logic tends to overlook the value of medical services, leading to a focus on cost-cutting rather than enhancing consumer experience [10][12] Group 4: Future Considerations - A potential solution to the pricing dilemma is itemized pricing, which would reflect the comprehensive service experience rather than just the cost of consumables [11][13] - The industry should aim for a pricing model that allows for fair profit margins for manufacturers while ensuring quality service and safety for consumers [13][14] - Ultimately, the question of who determines medical beauty service prices should involve multiple stakeholders, reflecting a consensus rather than unilateral control [14][16]

Group 1: Hong Kong Stocks - Lehua Entertainment (02306) surged over 24% due to strong market performance of its toy IP "WUKUKU," with multiple new products setting sales records and the theme song exceeding 1 billion views [1] - United Energy Group (00467) rose over 7% after signing a 15-year production increase contract with Uzbekistan's UNG, involving 57.8 billion cubic meters of oil and gas production, with an initial investment of $100 million to expand into Central Asia [1] - Smoore International (06969) fell over 3% as shareholder Yiwei Lithium Energy plans to reduce its stake by 3.5% (216 million shares), resulting in a decrease of its holding to 27.23%, no longer being the controlling shareholder [1] - New World Development (00200) dropped over 5% after completing a "2 for 1" rights issue, issuing 758 million shares and raising HKD 771 million, with oversubscription of 13 times [1] - Fourth Paradigm (06682) increased over 7% after launching AI solutions for the manufacturing industry, covering production optimization to supply chain intelligence upgrades [1] - Shandong High-Tech Holdings (00412) rose over 4% as Zhongtai Securities highlighted significant synergy between its new energy and digital infrastructure, with a data center PUE value of 1.15, enhancing financial integration [1] - KANAT Optical (02276) increased over 4% due to an explosion in the smart glasses market (e-commerce transactions up 8 times), with Meta collaborating with Oakley to launch AI glasses, positioning the company with leading 3C enterprises [1] Group 2: Other Notable Stocks - Sipai Health (00314) rose over 7% after partnering with Anruijiaer to develop customized insurance, planning to sell 6 pharmacies for 5.89 million to focus on core medical insurance business [2] - SF Express (09699) increased over 5% after raising its delivery service revenue cap for 2025/26 to HKD 12.8 billion / HKD 20.5 billion, with demand growth exceeding expectations [2] - Liufu Group (00590) fell over 3% as it projected a 40% decline in profits for the 2025 fiscal year, primarily due to gold hedging losses and high base effects from acquisition gains [2] - Zhenjiu Lidu (06979) rose over 4% after announcing Yao Annan as the "Cultural Heritage Ambassador" for liquor, leveraging Huawei-related topics to boost brand visibility [2] - Ideal Auto-W (02015) dropped over 4% as Meituan's Wang Xing sold 5.73 million shares for HKD 600 million, reducing his stake to 20.61% [2] - Health Road (02587) surged over 7% as its liver disease AI management platform was selected for Beijing's digital medical verification program, supporting WHO's "2030 Hepatitis Elimination" goal [2] - Gilead Sciences-B (01672) rose over 5% after its psoriasis oral drug ASC50 completed the first dosing in Phase I clinical trials in the U.S., targeting the IL-17 pathway [2] - China Silver Group (00815) increased over 10% after partnering with Zefeng Gold to acquire a 55% stake in a lead-zinc exploration company, gaining exploration rights over 50.8 square kilometers in Tibet [2] Group 3: U.S. Stocks - Verve Therapeutics (VERV.US) skyrocketed over 80% as Eli Lilly prepares to acquire the gene-editing company for up to $1.3 billion, with $1 billion as an upfront payment and $300 million contingent on specific clinical milestones [4] - Solar energy stocks plummeted, with Sunrun (RUN.US) down over 40%, Solaredge Technologies (SEDG.US) down over 41%, and First Solar (FSLR.US) down over 22%, following a Republican proposal in the U.S. Senate to terminate wind and solar tax credits by 2028, raising concerns about the industry's outlook [4] - Reddit (RDDT.US) rose over 6% after launching the AI advertising tool Reddit Insights, enhancing ad targeting through real-time user trend analysis [4] - Bitcoin-related stocks fell, with CleanSpark (CLSK.US) down over 7% and Riot Platforms (RIOT.US) down over 5%, as Bitcoin prices dropped nearly 2% to $105,580 amid escalating tensions in the Middle East and high leverage positions in the derivatives market [4] - AMD (AMD.US) continued to rise 0.56% after officially launching the Zen5 architecture Ryzen Threadripper processors, covering the workstation and desktop markets, with a market share close to 50% in China for Q1, although there are concerns about its cost-performance ratio [5] - Brain Regen Technologies (RGC.US) surged over 30% after announcing a 38-for-1 stock split, coupled with FDA clinical trial approval news, although its actual business has no revenue and a very small float, indicating significant retail speculation [6] - Jabil (JBL.US) rose over 8%, reaching a new all-time high of $202.5, with Q3 revenue increasing 15% year-on-year to $7.83 billion, raising its full-year revenue forecast to $29 billion and planning a $500 million investment to support AI data center infrastructure [6] - Niu Technologies (NIU.US) increased over 11% after launching its new NX Play electric motorcycle on Douyin, integrating a smart riding system to enhance user experience [6] - T-Mobile US (TMUS.US) fell nearly 4% as SoftBank sold 21.5 million shares at $224 each, a 3% discount, triggering market sell-off [6] - The pharmaceutical sector saw widespread declines, with Eli Lilly (LLY.US) down over 2% and Novo Nordisk (NVO.US) down over 3%, as concerns grew over the potential impact of the U.S. Senate tax bill on the industry, coupled with profit-taking ahead of some companies' earnings reports [6] - The gold sector declined, with Gold Fields (GFI.US) down over 2.1%, and spot gold fell 0.27% to $3,375.53, as easing tensions in the Middle East reduced safe-haven demand, alongside Citigroup's bearish long-term gold price forecast [7]

点评报告 2025 年 6 月 18 日 晨会纪要 第一创业证券研究所 分析师：郭强 证书编号：S1080524120001 电话：0755-23838533 邮箱：guoqiang@fcsc.com 核[心Ta观bl点e_：Summary] 一、宏观经济组： 证券研究报告 美国 5 月零售销售环比降 0.9%，创 2023 年 3 月以来的最大降幅，预期降 0.6%， 前值从升 0.1%修正为降 0.1%。 美国 5 月零售销售降幅超出预期，主要受汽车销量下滑拖累，而此前因担忧关税 引发的抢购潮已退去。不包括汽车和零部件的美国 5 月零售环比为-0.3%，预期 为 0.2%，前值为持平；而再扣除加油站的核心零售销售环比降 0.1%，预期升 0.3%， 前值为 0.1%。 另外，美联储周二公布的数据显示，5 月份工业产出指数环比为-0.2%，前值（4 月）数据修正后为增长 0.1%。其中，5 月份制造业产值小幅增长 0.1%，前值为 -0.5%。 市场方面，美股有所下滑，道指跌 0.7%,纳指跌 0.91%，标普 500 跌 0.84%；由于 美以冲突有扩大趋势引发避险需求，美元出现上涨，由 98.1 上涨至 ...

Core Viewpoint - New Oxygen (SY.O), known as the "first stock in internet medical beauty," is transitioning to offline institutions, having opened 23 self-operated medical beauty institutions across 9 cities in China within two years since May 2023 [1] Group 1: Business Expansion - In Q1 2025, New Oxygen's medical beauty chain business revenue reached 99 million yuan, a year-on-year increase of over 500% [1] - Management expects the revenue for this business in Q2 to be between 120 million and 140 million yuan [1] Group 2: Conflict with Suppliers - Tensions are rising between New Oxygen and upstream medical beauty material companies, particularly regarding the compliance issues of the "Aivilan" product used in New Oxygen's self-operated clinics [2] - The supplier, Changchun Shengboma Biological Materials Co., claims it does not guarantee the authenticity of the products sold by New Oxygen and has not trained their medical staff on the product [2][3] Group 3: Pricing Strategy - New Oxygen's pricing strategy involves selling a combination product called "Miracle Youth," which includes Aivilan and is priced at 5,999 yuan, significantly lower than the standard price of around 18,000 yuan for Aivilan alone [6][7] - This pricing strategy has raised concerns about whether the use of Aivilan for purposes beyond its approved indications constitutes off-label use [8] Group 4: Industry Dynamics - The conflict reflects broader issues in the medical beauty industry, where upstream manufacturers are losing pricing power amid fierce competition and price wars [10][11] - New Oxygen argues that its pricing strategy is a necessary correction to an unreasonable profit structure in the industry, aiming to make medical beauty services more accessible to a wider audience [13]

商贸零售 2025 年 06 月 16 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 48% 60% 2024-06 2024-10 2025-02 商贸零售 沪深300 相关研究报告 《高端中式黄金品牌"琳朝珠宝"获 得天使轮投资—行业周报》-2025.6.8 《老铺黄金、潮宏基发布新品，关注 差异化产品力优势—行业周报》 -2025.6.2 《医美化妆品 4 月月报：华熙生物两 款三类械抗衰产品获批，关注 618 国 货美妆表现—行业点评报告》 -2025.5.25 泡泡玛特跨界珠宝圈，旗下品牌 POPOP 首店开业 ——行业点评报告 | 黄泽鹏（分析师） | 陈思（联系人） | | --- | --- | | huangzepeng@kysec.cn | chensi@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790124070031 | chensi@kysec.cn 泡泡玛特跨界珠宝行业，旗下品牌 POPOP 首店于上海港汇恒隆开业 本周泡泡玛特旗下珠宝品牌 POPOP 首店于上海港汇恒隆开业。PO ...

Investment Rating - The report rates the investment outlook for the medical beauty regenerative anti-aging injection industry as "Positive" [5] Core Insights - The regenerative anti-aging injection agents are emerging materials that achieve facial rejuvenation through different mechanisms compared to hyaluronic acid and botulinum toxin [1] - The midstream of the regenerative anti-aging injection industry chain is identified as the segment with the highest added value, supported by regulatory compliance, technological innovation, and market demand [2] - Future trends in the industry include increased demand driven by an aging population, a shift towards non-surgical aesthetic procedures, and advancements in technology and materials that enhance product efficacy [3] Summary by Sections 1. Overview of the Medical Beauty Regenerative Anti-Aging Injection Industry - Medical beauty injection products are categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter being newly introduced in the domestic market [11] - Regenerative anti-aging injections include subclasses such as microsphere regeneration, collagen, and PDRN, each with distinct mechanisms and benefits [12][13] 2. Industry Chain Analysis - The midstream segment is characterized by high added value, with companies leveraging compliance, innovation, and production capabilities to establish competitive barriers [2][29] - The upstream involves raw material suppliers, while the downstream focuses on the distribution to end consumers through various channels [26] 3. Regulatory and Policy Environment - The industry is regulated by key agencies including the National Health Commission and the National Medical Products Administration, ensuring compliance across all stages from development to sales [43][46] 4. Market Size and Growth Potential - The market for medical beauty injections in China is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a CAGR of 25.3% [17] - The regenerative anti-aging segment is expected to see a significant increase, with its market share rising from 3% in 2019 to an estimated 31% by 2028 [20] 5. Investment Recommendations - Companies with a comprehensive industry chain layout and a strong product portfolio, such as Jinbo Biological and East China Pharmaceutical, are highlighted as having strong growth potential and investment value [3]

证券研究报告·行业跟踪周报·商贸零售 商贸零售行业跟踪周报 5 月我国非美出口展现韧性，重视非美出口 枢纽小商品城的战略地位 增持（维持） [Table_Tag] [周观点（注：文中"本周"指的 Table_Summary] 6 月 9 日至 6 月 15 日） 2025 年 06 月 16 日 证券分析师 吴劲草 证券分析师 阳靖 执业证书：S0600523020005 yangjing@dwzq.com.cn 证券分析师 郗越 执业证书：S0600524080008 xiy@dwzq.com.cn 执业证书：S0600520090006 wujc@dwzq.com.cn 证券分析师 石旖瑄 执业证书：S0600522040001 shiyx@dwzq.com.cn 证券分析师 张家璇 执业证书：S0600520120002 zhangjx@dwzq.com.cn 研究助理 王琳婧 执业证书：S0600123070017 wanglj@dwzq.com.cn 行业走势 -11% -4% 3% 10% 17% 24% 31% 38% 45% 52% 6/17/2024 10/15/2024 2/12/2025 ...

用户只需在唯芯美小程序内使用积分，即可完成与三大运营商的话费充值，全程自动处理，无需跳转、 无需等待，极大提升了积分使用效率和用户体验。 这不仅是技术上的一次跨越，更是积分生态迈向"生活支付化"的关键节点。唯芯美表示，未来积分将拓 展至更多公共支付场景，包括网费、电费、水费、燃气费等日常生活缴费系统，构建真正的"积分价值 闭环"。 2025年6月，唯芯美积分系统完成与中国移动（600941）BOSS系统、中国联通（600050）cBSS系统、 中国电信（601728）BS3.0系统的深度对接，通过"唯芯美积分池——API网关集群"架构，实现三网话费 的实时充值兑换。这标志着唯芯美成为首批将"消费医美积分"打通通信场景的创新品牌之一。 "这是消费医疗积分首次成为准通用货币。" ——中国电子商务创新推进联盟秘书长相关负责人 "唯芯美构建了'美丽—生活'的价值闭环，未来或可探索积分跨境兑换。" ——行业观察人士评论 "公用事业缴费是用户信任的终极试金石；当积分能交水电费，意味着品牌信用体系已比肩银行。" ——易观智库消费行业中心相关负责人 此次系统接入不仅提升了积分的价值感知，也增强了唯芯美品牌在用户信任与金融可拓 ...

Group 1 - The core viewpoint of the articles highlights the significant growth of Pop Mart, particularly its The Monsters series, which achieved sales exceeding 3.04 billion yuan in 2024, marking a year-on-year increase of 726.6% and surpassing the MOLLY series to become the most profitable IP for the company [1][5][19] - The recent surge in new consumption trends is attributed to the Z generation (born between 1995 and 2009), who represent 19% of China's population but account for 40% of total consumption power, indicating a strong willingness to spend on non-essential items like collectibles [5][19] - The consumption behavior of the Z generation reflects a shift towards emotional and social value, prioritizing identity and belonging over traditional material needs, which has led to a rise in products that cater to these desires, such as blind boxes and trendy toys [4][9][10] Group 2 - The Z generation's average disposable income reached 3,501 yuan in 2020, significantly higher than the national average of 2,682 yuan, enabling them to spend more on personal interests and emotional fulfillment [5][6] - The articles discuss the emergence of a "circle culture" among the Z generation, where purchasing items like blind boxes serves as a ticket to join specific social groups, enhancing their sense of belonging and identity [11][19] - Pop Mart's high gross margin of 63.9% in mainland China, along with the popularity of its products in the second-hand market, demonstrates the brand's ability to create high-value items that resonate with consumers' emotional and social needs [15][19]

Group 1: Consumer Trends - The demand side is expected to see weak consumption sentiment in 2024, with internal structural differentiation [1] - Investment opportunities in consumption are shifting from total volume to structure and even individual stocks, highlighting the emergence of new consumer groups and changing consumption psychology [1] - Companies can leverage social media for viral marketing effects, enhancing the spread and creating growth loops [1] Group 2: Gold and Jewelry Industry - The gold and jewelry industry is transitioning from a channel-driven era to a brand and product-driven era, influenced by innovations in craftsmanship and the rise of domestic brands [2] - Lao Pu Gold, as a pioneer in traditional gold, integrates cultural elements with modern aesthetics, benefiting from the rationalization of high-end consumption [2] Group 3: IP Toys - Demand for emotional value is driving the rise of IP-based cultural and toy consumption, particularly in character-based products [2] - Briklo adopts a standardized approach to create figurines, achieving high standardization and competitive pricing, leading to significant growth [2] Group 4: Medical Aesthetics - The medical aesthetics industry is characterized by high barriers and is driven by product and regulatory innovations, transitioning from hyaluronic acid to regenerative and collagen materials [3] - Jinbo Biotechnology, a key player in the collagen market, has seen growth following the approval of its recombinant collagen injection products, with a favorable competitive landscape [3] Group 5: New Tobacco Products - Innovations in new tobacco products are rapidly replacing traditional tobacco, driven by advancements in supply-side technologies [4] - Philip Morris International, as a pioneer in heated tobacco products, has seen significant user growth, with 32.2 million users expected by the end of 2024 [4]